Licofelone (Merckle)

IDrugs. 2003 Aug;6(8):802-8.

Abstract

EuroAlliance (a consortium of Alfa Wassermann SpA, Lacer SA and Merckle GmbH) is developing licofelone, a dual cyclooxygenase and 5-lipoxygenase inhibitor for the potential treatment of inflammatory disorders including osteoarthritis.

Publication types

  • Review

MeSH terms

  • Acetates / adverse effects
  • Acetates / pharmacokinetics
  • Acetates / pharmacology*
  • Acetates / therapeutic use
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Cyclooxygenase Inhibitors / adverse effects
  • Cyclooxygenase Inhibitors / pharmacokinetics
  • Cyclooxygenase Inhibitors / pharmacology*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / pathology
  • Lipoxygenase Inhibitors
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / pathology
  • Pyrroles / adverse effects
  • Pyrroles / pharmacokinetics
  • Pyrroles / pharmacology*
  • Pyrroles / therapeutic use
  • Structure-Activity Relationship

Substances

  • Acetates
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase Inhibitors
  • Lipoxygenase Inhibitors
  • Pyrroles
  • licofelone